Feb 24, 2021
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
Dec 21, 2020
RegeneRx Issues Year End Letter To Stockholders
Nov 09, 2020
Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trial
Oct 28, 2020
RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial
Oct 21, 2020
RegeneRx Closes Convertible Debt Financing
Oct 14, 2020
ARISE-3 Phase 3 Trial Completion Expected by End of 2020
Oct 12, 2020
RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome
Sep 08, 2020
New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19
Aug 19, 2020
RegeneRx Issues Update on Phase 3 Dry Eye Trial
Jun 02, 2020
RegeneRx Advisory on ARISE-3 Dry Eye Trial
May 27, 2020
RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic
May 14, 2020
RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259
Apr 20, 2020
RegeneRx Issues Advisory on ARISE-3 Dry Eye Trial
Mar 18, 2020
RegeneRx Issues Advisory on Dry Eye Trial Amid COVID-19 Virus
Feb 13, 2020
RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy
Feb 03, 2020
RegeneRx Partner Updates on Phase 3 Dry Eye Trial
Jan 22, 2020
RegeneRx Publishes Annual Letter to Shareholders
Nov 18, 2019
RegeneRx's Tb4 Significantly Reduces Damage in Ischemic Acute Kidney Injury Model
Oct 16, 2019
RegeneRx JV Partner Updates on Strategic Dry Eye Discussions
Sep 30, 2019
RegeneRx Partner Updates on ARISE-3 Clinical Trial